The FDA approved Guardant Health's Guardant360 CDx blood test as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Pfizer's Braftovi treatment combined with cetuximab and chemotherapy. This marks the 25th companion diagnostic indication for the platform and expands non-invasive genomic testing access. Guardant Health stock surged 2.27% to $118.37, trading at a 52-week high with strong technical momentum.

The pan-genomic and multi-gene panel testing market is projected to grow from US$ 8.9 billion in 2024 to US$ 25.9 billion by 2032, driven by a 12.04% CAGR. Growth is fueled by rising clinical adoption of genomics-driven diagnostics, FDA approvals of comprehensive genomic profiling tests, advances in NGS technology and bioinformatics, and expanding implementation across oncology, rare diseases, and preventive medicine. North America leads the market while Asia-Pacific shows the fastest growth.

Eventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals in Q3, but the position's value increased by approximately $50.70 million to $184.92 million due to the stock's 89% surge over the past year. The share reduction appears to be portfolio management rather than a loss of confidence, as Mirum posted strong Q3 revenue growth of 47% and raised full-year guidance, with the company now representing the fund's second-largest equity holding.

The Pre-Dx oncology market is entering a high-growth phase, driven by breakthrough non-invasive cancer detection technologies like liquid biopsy and multi-cancer early detection tests. The market is expected to generate substantial revenue growth, with North America leading and Asia Pacific showing the fastest growth potential.

The global oncology biomarker market is projected to grow from USD 34.16 billion in 2024 to USD 113.54 billion by 2034, with a 12.73% CAGR, driven by precision medicine, technological advances, and increasing cancer incidence.

The global breast cancer screening tests market is projected to grow from $4.75 billion in 2025 to $8.77 billion by 2034, with a 7.04% CAGR. Driven by increasing cancer awareness, technological advances in screening, and government initiatives, the market will see significant expansion in imaging and blood marker tests.

The global molecular diagnostics market is expected to grow from $23 billion in 2025 to $42.6 billion by 2030, driven by advances in genetic testing, cancer detection, and infectious disease diagnostics, with a 13.1% compound annual growth rate.

The global liquid biopsy market is projected to grow from $4.03 billion in 2025 to $7.05 billion by 2030, driven by rising cancer incidence, precision medicine advancements, and technological innovations in early disease detection.

Guardant Health reported strong Q2 2025 financial results, with revenue of $232.1 million (31% YoY growth), beating analyst estimates. The company saw significant progress in its oncology diagnostics and Shield screening business, raising full-year guidance to $915-$925 million.

The global Minimal Residual Disease (MRD) Testing Market is projected to reach $4.50 billion by 2030, with a 10.1% CAGR, driven by increasing cancer diagnostic needs and personalized medicine approaches.

The report highlights the rapid advancements in the molecular diagnostics for cancer market, driven by trends like personalized medicine, pharmacogenomics, and liquid biopsy. It profiles over 140 companies and provides extensive data and forecasts to aid decision-making in this evolving global market.

The global epigenetics market is projected to grow from $4.8 billion in 2024 to $8.5 billion by 2029, driven by factors like rising cancer rates, technological advances, and the trend towards precision medicine.